| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
| US5972990 | NOVARTIS | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
Oct, 2016
(7 years ago) | |
|
US5972990 (Pediatric) | NOVARTIS | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
Apr, 2017
(7 years ago) | |
| US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
|
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) | |
Diovan is owned by Novartis.
Diovan contains Valsartan.
Diovan has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Diovan are:
- US5399578*PED
- US5972990
- US5972990*PED
- US6294197
- US6294197*PED
Diovan was authorised for market use on 14 August, 2002.
Diovan is available in tablet;oral dosage forms.
Diovan can be used as use of valsartan to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction, treatment of hypertension.
The generics of Diovan are possible to be released after 19 April, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 19, 2024 |
Drugs and Companies using VALSARTAN ingredient
Market Authorisation Date: 14 August, 2002
Treatment: Use of valsartan to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction; Treatment of hypertensi...
Dosage: TABLET;ORAL
DIOVAN family patents
